We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer

By MedImaging International staff writers
Posted on 22 Jan 2024
Print article
Image: A newly developed PET imaging agent is effective in identifying medullary thyroid cancer (Photo courtesy of 123RF)
Image: A newly developed PET imaging agent is effective in identifying medullary thyroid cancer (Photo courtesy of 123RF)

Medullary thyroid cancer (MTC) represents about 3% of all thyroid cancer cases and is notably rare. It arises from different cells compared to other thyroid cancers, necessitating distinct imaging and treatment approaches. The overexpression of the cholecystokinin-2 receptor (CCK-2R) on most MTC cells has led to the development of various compounds targeting this receptor. However, many of these compounds suffer from low metabolic stability, which hampers their effectiveness in radioligand therapy. Now, a newly developed PET imaging agent has shown promise in both preclinical and clinical studies for identifying MTC, suggesting its potential as a theranostic tool in clinical settings.

In a study conducted by researchers at Stanford University (Stanford, CA, USA), three compounds—DOTA-CCK-66, DOTA-CCK 66.2, and DOTA-MGS5—were each labeled with different isotopes: 64Cu, 67Ga, and 177Lu. The team evaluated the CCK-2R affinity of these radiolabeled compounds on MTC cells. All compounds displayed high affinity, but DOTA-CCK-66 was selected for further study due to its superior in vitro properties, leading to the exclusion of DOTA-CCK-66.2 from subsequent analyses.

Following this, the researchers carried out in vivo stability, biodistribution, imaging, and competition studies using mice with CCK-2R-expressing tumors. Based on its comprehensive in vitro and in vivo performance, 68Ga-DOTA-CCK-66 was chosen for a proof-of-concept PET/CT application. Subsequently, two MTC patients underwent 68Ga-DOTA-CCK-66 PET/CT scans. The scans revealed that the compound was well tolerated by the patients, exhibited favorable biodistribution, and demonstrated high activity accumulation in the tumors.

“Due to increased in vivo stability, our compound reveals favorable tumor uptake as well as an improved activity clearance from off-target tissues,” said Constantin Lapa, MD, director of nuclear medicine at University Hospital Augsburg. “This could result in enhanced lesion detection in PET imaging and additionally enable targeted MTC radioligand therapy.”

Related Links:
Stanford University

Gold Member
Solid State Kv/Dose Multi-Sensor
Ultrasound Color LCD
FMT Radiographic Suite
AdvantagePlus ML1
1.5T Superconducting MRI System
uMR 680

Print article



view channel
Image: The pathways in the brain highlighted are those most affected by concussion (Photo courtesy of Benjamin Hacker et al)

AI Model Diagnoses Traumatic Brain Injury from MRI Scans With 99% Accuracy

A concussion is a type of traumatic brain injury that may lead to temporary disruptions in brain function. Occurring from incidents such as sports injuries, whiplash, or a simple bump to the head, many... Read more


view channel
Image: The new FDA-cleared AI-enabled applications have been integrated into the EPIQ CVx and Affiniti CVx ultrasound systems (Photo courtesy of Royal Philips)

Next-Gen AI-Enabled Cardiovascular Ultrasound Platform Speeds Up Analysis

Heart failure is a significant global health challenge, affecting approximately 64 million individuals worldwide. It is associated with high mortality rates and poor quality of life, placing a considerable... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Calantic Digital Solutions is an orchestrated suite of AI radiology solutions that aims to transform radiology (Photo courtesy of Bayer)

Bayer and Rad AI Collaborate on Expanding Use of Cutting Edge AI Radiology Operational Solutions

Imaging data constitutes approximately 90% of all medical data, with the volume of such data continuously expanding, thereby significantly increasing the workload for radiologists amid existing resource limitations.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.